DOCSLIB.ORG

The Effect of Μ-Opioid Receptor Polymorphisms on Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Μ-Opioid Receptor Polymorphisms on Receptor The Effect of μ-Opioid Receptor Polymorphisms on Receptor Signalling Systems Alisa Knapman (BMedSci Hons) Faculty of Human Science Australian School of Advanced Medicine Macquarie University 2014 A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy Table of Contents Chapter 1: Introduction 1 1.1 Opioid Receptors 2 1.1.1 MOP 4 1.1.2 DOPr 5 1.1.3 KOPr 5 1.1.4 NOPr 6 1.2 Opioid receptors are G protein coupled receptors 7 1.3 MOPr Structure and Signalling 8 1.4 MOPr Effectors 9 1.4.1 MOPr inhibition of adenylyl cyclase 9 1.4.2 MOPr activation of potassium channels 11 1.4.3 MOPr inhibition of calcium channels 12 1.4.4 MOPr release of intracellular calcium 13 1.4.5 MOPr and the MAP kinase cascade 14 1.4.6 Other MOPr effectors 15 1.4.7 MOPr desensitisation and endocytosis 16 1.5 MOPr Ligands 18 1.5.1 Endogenous MOPr ligands 18 1.5.2 Exogenous MOPr ligands 18 1.5.3 Ligand affinity and efficacy 19 1.6 Ligand-biased signalling at MOPr 20 1.7 OPRM1 Polymorphisms 22 1.8 MOPr variants and differential signalling 25 i Chapter 2: Review Article 27 “Cellular signalling of non-synonymous single nucleotide polymorphisms of the human μ-opioid receptor” Hypotheses and Aims 77 Methods - Overview 78 Chapter 3: Research Article 79 “A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells” Chapter 4: Research Article 107 “A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells” Results - Overview 135 Chapter 5: Research Article 137 “ Buprenorphine signalling is compromised at the N40D polymorphism of the human μ-opioid receptor in vitro” Chapter 6: Research Article 185 “ The A6V polymorphism of the human μ-opioid receptor negatively impacts signalling of morphine and endogenous opioids in vitro” Chapter 7: Research Article (in preparation) 233 “Mu-opioid receptor polymorphisms differentially affect receptor signalling via adenylyl cyclase inhibition and ERK1/2 phosphorylation” ii Chapter 8: General Discussion and Summary 263 References 275 Appendix: Book Chapter 329 “Fluorescence-Based, High-Throughput Assays for µ-Opioid Receptor Activation using Membrane Potential Sensitive Dye” iii List of Figures 2.1 Naturally occurring non-synonymous OPRM1 variants 35 3.1 Stimulating adenylyl cyclase hyperpolarises CHO cells 87 3.2 Opioids inhibit forskolin stimulated membrane hyperpolarisation 89 in CHO cells 3.3 Protein kinase A activators mimic the effects of forskolin 93 3.4 Forskolin induced hyperpolarisation is dependent on extracellular 95 K concentration 4.1 Example traces of fluorescent signal in the membrane potential assay 114 4.2 Trace of fluorescent signal illustrating reversal of DAMGO stimulated 117 decrease in signal by MOPr antagonist naloxone 4.3 DAMGO and morphine stimulated hyperpolarisation is PTX sensitive 120 4.4 Decreasing [K]Ex increases maximum change in fluorescent signal 120 4.5 Nigericin causes maximum membrane hyperpolarisation 121 4.6 DAMGO, morphine, buprenorphine and pentazocine concentration- 121 response curves for GIRK activation 4.7 Desensitisation of MOPr signalling in AtT-20 cells 123 5.1 Saturation binding curve of [3H]DAMGO in intact CHO-MOPr cells 149 5.2 DAMGO inhibits adenylyl cyclase and activates ERK1/2 in CHO cells 153 expressing MOPr-WT and MOPr-N40D 5.3 Endogenous opioids inhibit adenylyl cyclase and activate ERK1/2 in 155 CHO cells expressing MOPr-WT or MOPr-N40D 5.4 Buprenorphine inhibits adenylyl cyclase and activates ERK1/2 less 157 effectively in CHO cells expressing MOPr-N40D 5.5 Fentanyl, oxycodone and methadone inhibit adenylyl cyclase and activate 159 ERK1/2 in CHO cells expressing MOPr-WT or MOPr-N40D 5.6 DAMGO causes membrane hyperpolarisation in AtT-20 cells expressing 164 MOPr-WT 5.7 Buprenorphine is less potent for GIRK activation in AtT-20 cells 167 expressing MOPr-N40D 6.1 Saturation binding curve of [3H]DAMGO in intact CHO-MOPr-WT 196 and CHO-MOPr-A6V cell 6.2 DAMGO inhibits adenylyl cyclase and activates ERK1/2 in CHO cells 199 expressing MOPr-WT and MOPr-A6V iv 6.3 Morphine, buprenorphine and pentazocine inhibition of adenylyl cyclase 203 and activation of ERK1/2 is compromised in CHO cells expressing MOPr-A6V 6.4 Endogenous opioid inhibition of adenylyl cyclase and activation of 207 ERK1/2 is significantly affected by the A6V variant in CHO cells expressing MOPr 6.5 Fentanyl, methadone and oxycodone inhibition of adenylyl cyclase 211 and activation of ERK1/2 is significantly affected by the A6V variant in CHO cells expressing MOPr 6.6 DAMGO causes membrane hyperpolarisation in AtT-20 cells expressing 213 MOPr-WT 6.7 Morphine activates GIRK less effectively in AtT20 cells expressing 215 MOPr-A6V 7.1 DAMGO, morphine, buprenorphine and pentazocine inhibit adenylyl 245 cyclase and activate ERK1/2 in CHO cells expressing MOPr-WT or MOPr variants 7.2 Endogenous opioids inhibit adenylyl cyclase and activate ERK1/2 247 in CHO cells expressing MOPr-WT or MOPr variants 7.3 Methadone, fentanyl and oxycodone inhibit adenylyl cyclase and activate ERK1/2 in CHO cells expressing MOPr-WT or MOPr variants 251 7.4 High concentrations of methadone and fentanyl cause membrane 252 depolarisation in CHO-MOPr-L85I cells v List of Tables 2.1 Summary of non-synonymous MOPr variants 38 2.2 Summary of key findings about MOPr SNP signalling 48 - 51 4.1 Potencies and efficacies of the range of structurally distinct 119 opioid ligands tested using the membrane potential assay 5.1 Summary of opioid efficacy and potency in assays of AC 160 inhibition in CHO cells expressing MOPr-WT and MOPr-N40D 5.2 Summary of opioid efficacy and potency in assays of ERK1/2 161 phosphorylation in CHO cells expressing MOPr-WT and MOPr-N40D 5.3 Summary of opioid efficacy and potency in assays of GIRK 168 activation in in CHO cells expressing MOPr-WT and MOPr-N40D 6.1 Summary of opioid efficacy and potency in assays of AC 200 inhibition in CHO cells expressing MOPr-WT and MOPr-A6V 6.2 Summary of opioid efficacy and potency in assays of ERK1/2 208 phosphorylation in CHO cells expressing MOPr-WT and MOPr-A6V 6.3 Summary of opioid efficacy and potency in assays of GIRK 216 activation in in CHO cells expressing MOPr-WT and MOPr-A6V 7.1 Surface receptor expression and DAMGO Kd for MOPr 242 variants in CHO cells 7.2 Forskolin and PMA responses in MOPr variants 242 7.3 Summary of opioid efficacy and potency in assays of AC 254 inhibition in CHO cells expressing MOPr-WT and MOPr variants 7.4 Summary of opioid efficacy and potency in assays of ERK1/2 255 phosphorylation in CHO cells expressing MOPr-WT and MOPr variants vi Abbreviations 4-AP 4-aminopyridine aa amino acid AC adenylyl cyclase ACTH adrenocorticotropic hormone Akt protein kinase B β-CNA β-chlornaltrexamine β-FNA β-funal trexamine BSA bovine serum albumin CaM calmodulin cAMP cyclic adenosine monophosphate CaMKII Ca2+/calmodulin-dependent protein kinase II CHO Chinese Hamster Ovary CRC concentration-response curve CRE cAMP response element DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin DMEM Dulbecco’s Modified Eagle Medium DOPr δ-opioid receptor DPDPE [2-Dpenicillamin, 5-Dpenicillamin]-enkephalin ECL extracellular loop EGFR epidermal growth factor receptor ELISA enzyme-linked immunosorbent assay EM1 endomorphin 1 EM2 endomorphin 2 EPAC exchange signal activated by cAMP vii ERK extracellular signal regulated kinase FSK forskolin GIRK G protein gated, inwardly rectifying potassium channel GLR3 glycine receptor α3 GPCR G protein couple receptors GRK G protein coupled receptor kinase HBSS Hanks balanced salt solution hMOPr human µ-opioid receptor HPA hypothalamic-pituitary-adrenal ICa voltage gated Ca channels ICL intracellular loop IP3 inositol (1,4,5) triphosphate JNK Jun N-terminal kinase KO knock-out KOPr κ-opioid receptor M-6-G morphine-6-glucuronide MAPK mitogen activated protein kinase MOPr µ-opioid receptor mRNA messenger ribonucleic acid N/OFQ nociceptin/orphanin FQ NMDA N-methyl-d-aspartate NOPr nociceptin/orphanin FQ receptor NR1 NMDA receptor 1 OPRD1 opioid receptor δ 1 viii OPRK1 opioid receptor κ 1 OPRL1 opioid receptor-like 1 OPRM1 opioid receptor mu 1 p38MAPK p38 mitogen activated kinase PAG periaqueductal grey pDyn prodynorphin pENK proenkephalin pERK phosphorylated ERK1/2 PI3K phosphatidylinositol-3 kinase PKA protein kinase A PKC protein kinase C POMC proopiomelanocortin PLC phospholipase C PTX pertussis toxin SNP single nucleotide polymorphism STAT5 signal transducer and activator of transcription 5 TEA tetraethylammonium TM transmembrane TRPV1 transient receptor potential cation channel, subfamily V, member 1 ix x Summary There is significant variation in individual response to opioid drugs, one cause of which is likely to be polymorphisms on the opioid receptors themselves. The μ-opioid receptor (MOPr) is the primary site of action for most analgesic opioids. Previous studies have identified a number of naturally occurring single nucleotide polymorphisms (SNPs) in the coding region of MOPr. The A118G SNP (N40D), present at allelic frequencies ranging from 10 – 50%, has been associated with diverse phenotypic effects as well as differences in receptor signalling in vitro, with little consistency between studies. Few studies have examined the consequences of other MOPr polymorphisms on receptor function, or potential ligand and pathway specific effects. In this study, the relative potency and efficacy of a range of clinically important and/or structurally distinct opioid ligands were assessed in Chinese hamster ovary (CHO) cells and mouse pituitary neuroblastoma (AtT- 20) cells stably transfected with human wild type MOPr and 5 naturally occurring MOPr variants, N40D, A6V, L85I, R260H and R265H.
Load more

Recommended publications
  • The in Vitro Binding Properties of Non-Peptide AT1 Receptor Antagonists
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2002; 5 (1), 75-82 The In Vitro Binding Properties of Non-Peptide AT1 Receptor Antagonists Vanderheyden PML, Fierens FLP, Vauquelin G, Verheijen I Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria REVIEWS Binding of Non-Peptide AT1 Receptor Antagonists J Clin Basic Cardiol 2002; 5: 75 The In Vitro Binding Properties of Non-Peptide AT1 Receptor Antagonists P. M. L. Vanderheyden, I. Verheijen, F. L. P. Fierens, G. Vauquelin A major breakthrough in the development of AT1 receptor antagonists as promising antihypertensive drugs, was the synthe- sis of potent and selective non-peptide antagonists for this receptor. In the present manuscript an overview of the in vitro binding properties of these antagonists is discussed. In particular, CHO cells expressing human AT1 receptors offer a well- defined and efficient experimental system, in which antagonist binding and inhibition of angiotensin II induced responses could be measured. From these studies it appeared that all investigated antagonists were competitive with respect to angiotensin II and bind to a common or overlapping binding site on the receptor. Moreover this model allowed us to describe the mecha- nism by which certain antagonists depress the maximal angiotensin II responsiveness in vascular contraction studies. Insur- mountable inhibition was found to be related to the dissociation rate of the antagonist-AT1 receptor complex. The almost complete (candesartan), partially insurmountable inhibition (irbesartan, EXP3174, valsartan) or surmountable inhibition (losartan), was explained by the ability of the antagonist-receptor complex to adopt a fast and slow reversible state.
    [Show full text]
  • Atrazine and Cell Death Symbol Synonym(S)
    Supplementary Table S1: Atrazine and Cell Death Symbol Synonym(s) Entrez Gene Name Location Family AR AIS, Andr, androgen receptor androgen receptor Nucleus ligand- dependent nuclear receptor atrazine 1,3,5-triazine-2,4-diamine Other chemical toxicant beta-estradiol (8R,9S,13S,14S,17S)-13-methyl- Other chemical - 6,7,8,9,11,12,14,15,16,17- endogenous decahydrocyclopenta[a]phenanthrene- mammalian 3,17-diol CGB (includes beta HCG5, CGB3, CGB5, CGB7, chorionic gonadotropin, beta Extracellular other others) CGB8, chorionic gonadotropin polypeptide Space CLEC11A AW457320, C-type lectin domain C-type lectin domain family 11, Extracellular growth factor family 11, member A, STEM CELL member A Space GROWTH FACTOR CYP11A1 CHOLESTEROL SIDE-CHAIN cytochrome P450, family 11, Cytoplasm enzyme CLEAVAGE ENZYME subfamily A, polypeptide 1 CYP19A1 Ar, ArKO, ARO, ARO1, Aromatase cytochrome P450, family 19, Cytoplasm enzyme subfamily A, polypeptide 1 ESR1 AA420328, Alpha estrogen receptor,(α) estrogen receptor 1 Nucleus ligand- dependent nuclear receptor estrogen C18 steroids, oestrogen Other chemical drug estrogen receptor ER, ESR, ESR1/2, esr1/esr2 Nucleus group estrone (8R,9S,13S,14S)-3-hydroxy-13-methyl- Other chemical - 7,8,9,11,12,14,15,16-octahydro-6H- endogenous cyclopenta[a]phenanthren-17-one mammalian G6PD BOS 25472, G28A, G6PD1, G6PDX, glucose-6-phosphate Cytoplasm enzyme Glucose-6-P Dehydrogenase dehydrogenase GATA4 ASD2, GATA binding protein 4, GATA binding protein 4 Nucleus transcription TACHD, TOF, VSD1 regulator GHRHR growth hormone releasing
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Constitutive Activation of G Protein-Coupled Receptors and Diseases: Insights Into Mechanisms of Activation and Therapeutics
    Pharmacology & Therapeutics 120 (2008) 129–148 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: S. Enna Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics Ya-Xiong Tao ⁎ Department of Anatomy, Physiology and Pharmacology, 212 Greene Hall, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA article info abstract The existence of constitutive activity for G protein-coupled receptors (GPCRs) was first described in 1980s. In Keywords: 1991, the first naturally occurring constitutively active mutations in GPCRs that cause diseases were reported G protein-coupled receptor Disease in rhodopsin. Since then, numerous constitutively active mutations that cause human diseases were reported Constitutively active mutation in several additional receptors. More recently, loss of constitutive activity was postulated to also cause Inverse agonist diseases. Animal models expressing some of these mutants confirmed the roles of these mutations in the Mechanism of activation pathogenesis of the diseases. Detailed functional studies of these naturally occurring mutations, combined Transgenic model with homology modeling using rhodopsin crystal structure as the template, lead to important insights into the mechanism of activation in the absence of crystal structure of GPCRs in active state. Search for inverse Abbreviations: agonists on these receptors will be critical for correcting the diseases cause by activating mutations in GPCRs. ADRP, autosomal dominant retinitis pigmentosa Theoretically, these inverse agonists are better therapeutics than neutral antagonists in treating genetic AgRP, Agouti-related protein AR, adrenergic receptor diseases caused by constitutively activating mutations in GPCRs. CAM, constitutively active mutant © 2008 Elsevier Inc.
    [Show full text]
  • TRPV1 Is a Physiological Regulator of Μ-Opioid Receptors
    TRPV1 is a physiological regulator of μ-opioid receptors Paul C. Scherera,1, Nicholas W. Zaccora,1, Neil M. Neumannb, Chirag Vasavdaa, Roxanne Barrowa, Andrew J. Ewaldb, Feng Raoc, Charlotte J. Sumnera,d, and Solomon H. Snydera,e,f,2 aThe Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205; bDepartment of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205; cDepartment of Biology, Southern University of Science and Technology, Shenzhen, Guangdong, China 518055; dDepartment of Neurology and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205; eDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205; and fDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205 Contributed by Solomon H. Snyder, November 8, 2017 (sent for review September 29, 2017; reviewed by Marc G. Caron and Gavril W. Pasternak) Opioids are powerful analgesics, but also carry significant side effects the field of pain biology. TRPV1 is a nociceptor activated by and abuse potential. Here we describe a modulator of the μ-opioid noxious heat, protons, and capsaicin, the pungent component of receptor (MOR1), the transient receptor potential channel subfamily chili peppers. TRPV1 is a nonselective cation channel, but pre- vanilloid member 1 (TRPV1). We show that TRPV1 binds MOR1 and dominantly fluxes calcium ions and is widely expressed in small- blocks opioid-dependent phosphorylation of MOR1 while leaving G diameter C-fiber neurons (16–18). TRPV1 is often coexpressed protein signaling intact. Phosphorylation of MOR1 initiates recruit- with MOR1 in peripheral nervous tissues, including dorsal root ment and activation of the β-arrestin pathway, which is responsible ganglion cells (DRGs), and is expressed at low levels throughout for numerous opioid-induced adverse effects, including the devel- the brain (2, 19–21).
    [Show full text]
  • Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020)
    University of Kentucky UKnowledge Theses and Dissertations--Medical Sciences Medical Sciences 2020 Involvement of the Sigma-1 Receptor in Methamphetamine- Mediated Changes to Astrocyte Structure and Function Richik Neogi University of Kentucky, [email protected] Author ORCID Identifier: https://orcid.org/0000-0002-8716-8812 Digital Object Identifier: https://doi.org/10.13023/etd.2020.363 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Neogi, Richik, "Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020). Theses and Dissertations--Medical Sciences. 12. https://uknowledge.uky.edu/medsci_etds/12 This Master's Thesis is brought to you for free and open access by the Medical Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Medical Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Heterodimerization of Μ and Δ Opioid Receptors: a Role in Opiate Synergy
    The Journal of Neuroscience, 2000, Vol. 20 RC110 1of5 Heterodimerization of ␮ and ␦ Opioid Receptors: A Role in Opiate Synergy I. Gomes, B. A. Jordan, A. Gupta, N. Trapaidze, V. Nagy, and L. A. Devi Departments of Pharmacology and Anesthesiology, New York University School of Medicine, New York, New York 10016 Opiate analgesics are widely used in the treatment of severe ␮-selective ligands results in a significant increase in the bind- pain. Because of their importance in therapy, different strate- ing of a ␦ receptor agonist. This robust increase is also seen in gies have been considered for making opiates more effective SKNSH cells that endogenously express both ␮ and ␦ recep- while curbing their liability to be abused. Although most opiates tors. Furthermore, we find that a ␦ receptor antagonist en- exert their analgesic effects primarily via ␮ opioid receptors, a hances both the potency and efficacy of the ␮ receptor signal- number of studies have shown that ␦ receptor-selective drugs ing; likewise a ␮ antagonist enhances the potency and efficacy can enhance their potency. The molecular basis for these find- of the ␦ receptor signaling. A combination of agonists (␮ and ␦ ings has not been elucidated previously. In the present study, receptor selective) also synergistically binds and potentiates we examined whether heterodimerization of ␮ and ␦ receptors signaling by activating the ␮–␦ heterodimer. Taken together, could account for the cross-modulation previously observed these studies show that heterodimers exhibit distinct ligand between these two receptors. We find that co-expression of ␮ binding and signaling characteristics. These findings have im- and ␦ receptors in heterologous cells followed by selective portant clinical ramifications and may provide new foundations immunoprecipitation results in the isolation of ␮–␦ het- for more effective therapies.
    [Show full text]
  • Activation of G Protein-Coupled Estradiol Receptor 1 in The
    Quigley et al. Biology of Sex Differences (2021) 12:46 https://doi.org/10.1186/s13293-021-00389-w RESEARCH Open Access Activation of G protein-coupled estradiol receptor 1 in the dorsolateral striatum enhances motivation for cocaine and drug- induced reinstatement in female but not male rats Jacqueline A. Quigley1,2* , Molly K. Logsdon2, Brianna C. Graham1, Kendra G. Beaudoin1 and Jill B. Becker1,2 Abstract Background: Estradiol potentiates drug-taking behaviors, including motivation to self-administer cocaine and reinstatement of drug-seeking after extinction in females, but not males. The dorsolateral stratum (DLS) is a region of the brain implicated in mediating drug-seeking behaviors and, more specifically, is a target brain area to study how estradiol regulates these behaviors. The estradiol receptors α, β, and G protein-coupled estradiol receptor 1 (GPER1) are all present in the DLS. In this study, the effects of activating GPER1 in the DLS on drug-seeking are investigated. Methods: Gonad-intact male and female rats were trained to self-administer cocaine (0.4 mg/kg/inf) on a fixed- ratio 1 schedule of reinforcement. For 4 weeks, animals underwent testing on a progressive ratio schedule of reinforcement to determine their motivation to attain cocaine. Halfway through progressive ratio testing, a selective agonist targeting GPER1 (G1) was administered intra-DLS to determine the contribution of GPER1 activation on motivation for cocaine. The effects of intra-DLS GPER1 activation on drug-induced reinstatement after extinction were subsequently determined. Results: Activation of GPER1, via intra-DLS G1 administration, potentiated females’ motivation to self-administer cocaine.
    [Show full text]
  • Binding Pathway of Opiates to Μ-Opioid Receptors Revealed by Unsupervised Machine Learning
    Binding Pathway of Opiates to µ-Opioid Receptors Revealed by Unsupervised Machine Learning Amir Barati Farimani§, Evan N. Feinberg§, Vijay S. Pande1 Department of Chemistry, Stanford University, Stanford, California 94305 [§] The authors equally contributed to this work Abstract Many important analgesics relieve pain by binding to the µ-Opioid Receptor (µOR), which makes the µOR among the most clinically relevant proteins of the G Protein Coupled Receptor (GPCR) family. Despite previous studies on the activation pathways of the GPCRs, the mechanism of opiate binding and the selectivity of µOR are largely unknown. We performed extensive molecular dynamics (MD) simulation and analysis to find the selective allosteric binding sites of the µOR and the path opiates take to bind to the orthosteric site. In this study, we predicted that the allosteric site is responsible for the attraction and selection of opiates. Using Markov state models and machine learning, we traced the pathway of opiates in binding to the orthosteric site, the main binding pocket. Our results have important implications in designing novel analgesics. Introduction The most powerful analgesic and addictive properties of opiates are mediated by the µ-Opioid Receptor (µOR).1, 2 Since this receptor is primarily responsible for the effects of opium, the µOR 1 Corresponding Author, e-mail: [email protected], web: https://pande.stanford.edu/ is one of the oldest drug targets for the discovery of analgesics.3 µOR activation results in signaling through the heterotrimeric G protein
    [Show full text]
  • Evolution of the Neuropeptide Y and Opioid Systems and Their Genomic
    It's time to try Defying gravity I think I'll try Defying gravity And you can't pull me down Wicked List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. I Sundström G, Larsson TA, Brenner S, Venkatesh B, Larham- mar D. (2008) Evolution of the neuropeptide Y family: new genes by chromosome duplications in early vertebrates and in teleost fishes. General and Comparative Endocrinology Feb 1;155(3):705-16. II Sundström G, Larsson TA, Xu B, Heldin J, Lundell I, Lar- hammar D. (2010) Interactions of zebrafish peptide YYb with the neuropeptide Y-family receptors Y4, Y7, Y8a and Y8b. Manuscript III Sundström G, Xu B, Larsson TA, Heldin J, Bergqvist CA, Fredriksson R, Conlon JM, Lundell I, Denver RJ, Larhammar D. (2010) Characterization of the neuropeptide Y system's three peptides and six receptors in the frog Silurana tropicalis. Manu- script IV Dreborg S, Sundström G, Larsson TA, Larhammar D. (2008) Evolution of vertebrate opioid receptors. Proc Natl Acad Sci USA Oct 7;105(40):15487-92. V Sundström G, Dreborg S, Larhammar D. (2010) Concomitant duplications of opioid peptide and receptor genes before the origin of jawed vertebrates. PLoS One May 6;5(5):e10512. VI Sundström G, Larsson TA, Larhammar D. (2008) Phylogenet- ic and chromosomal analyses of multiple gene families syntenic with vertebrate Hox clusters. BMC Evolutionary Biology Sep 19;8:254. VII Widmark J, Sundström G, Ocampo Daza D, Larhammar D. (2010) Differential evolution of voltage-gated sodium channels in tetrapods and teleost fishes.
    [Show full text]
  • Κ-Opioid Receptor Agonists Modulate Visceral Nociception at a Novel
    The Journal of Neuroscience, August 1, 2000, 20(15):5874–5829 ␬-Opioid Receptor Agonists Modulate Visceral Nociception at a Novel, Peripheral Site of Action S. K. Joshi,1 Xin Su,1 Frank Porreca,2 and G. F. Gebhart1 1Department of Pharmacology, College of Medicine, The University of Iowa, Iowa City, Iowa 52242, and 2Department of Pharmacology, University of Arizona, Tucson, Arizona 85721 ␬-opioid receptor agonists (␬-ORAs) have been shown to mod- tions of DAMGO or deltorphin; a complete recovery of antinoci- ulate visceral nociception through an interaction with a periph- ceptive actions of the ␬-ORA EMD 61,753 was observed 10 d eral, possibly novel, ␬-opioid-like receptor. We used in the after the termination of antisense ODN treatment. In contrast, the present experiments an antisense strategy to further explore the ability of EMD 61,753 to dose-dependently attenuate responses hypothesis that ␬-ORA effects in the colon are produced at a site of pelvic nerve afferent fibers to noxious colonic distension was different from the cloned ␬-opioid receptor (KOR). An antisense unaffected in the same rats in which the antisense ODN effec- oligodeoxynucleotide (ODN) to the cloned rat KOR was admin- tively knocked-down the KOR as assessed in the formalin test. istered intrathecally (12.5 ␮g, twice daily for 4 d) to specifically Additionally, Western blot analysis demonstrated a significant knock-down the cloned KOR. Efficacy of the KOR antisense ODN downregulation of KOR protein in the L4-S1 dorsal root ganglia treatment was behaviorally evaluated by assessing the antinoci- of antisense, but not mismatch ODN-treated rats.
    [Show full text]
  • Substance P Receptor (NK1) in the Trigeminal Dorsal Horn
    The Journal of Neuroscience, June 1, 2000, 20(11):4345–4354 ␮-Opioid Receptors Often Colocalize with the Substance P Receptor (NK1) in the Trigeminal Dorsal Horn Sue A. Aicher, Ann Punnoose, and Alla Goldberg Weill Medical College of Cornell University, Department of Neurology and Neuroscience, Division of Neurobiology, New York, New York 10021 Substance P (SP) is a peptide that is present in unmyelinated neurons may contain receptors at sites distant from the peptide primary afferents to the dorsal horn and is released in response release site. With regard to opioid receptors, we found that to painful or noxious stimuli. Opiates active at the ␮-opiate many MOR-immunoreactive dendrites also contain NK1 (32%), receptor (MOR) produce antinociception, in part, through mod- whereas a smaller proportion of NK1-immunoreactive dendrites ulation of responses to SP. MOR ligands may either inhibit the contain MOR (17%). Few NK1 dendrites (2%) were contacted release of SP or reduce the excitatory responses of second- by MOR-immunoreactive afferents. These results provide the order neurons to SP. We examined potential functional sites for first direct evidence that MORs are on the same neurons as interactions between SP and MOR with dual electron micro- NK1 receptors, suggesting that MOR ligands directly modulate scopic immmunocytochemical localization of the SP receptor SP-induced nociceptive responses primarily at postsynaptic (NK1) and MOR in rat trigeminal dorsal horn. We also examined sites, rather than through inhibition of SP release from primary the relationship between SP-containing profiles and NK1- afferents. This colocalization of NK1 and MORs has significant bearing profiles. We found that 56% of SP-immunoreactive implications for the development of pain therapies targeted at terminals contact NK1 dendrites, whereas 34% of NK1- these nociceptive neurons.
    [Show full text]